Want to see AMGN full AI Analyst Report?
AMGN Stock Chart & Stats
$355.30
-$0.21(-0.08%)
At close: 4:00 PM EST
$355.30
-$0.21(-0.08%)
Day’s Range― - ―
52-Week Range$269.77 - $391.29
Previous CloseN/A
Volume614.18K
Average Volume (3M)2.81M
Market Cap
$198.61B
Enterprise Value$229.68B
Total Cash (Recent Filing)$12.04B
Total Debt (Recent Filing)$57.32B
Price to Earnings (P/E)25.1
Beta0.34
Next Earnings
Aug 04, 2026EPS Estimate
5.6Next Dividend Ex-DateN/A
Dividend Yield3%
Share Statistics
EPS (TTM)14.48
Shares Outstanding539,708,250
10 Day Avg. Volume2,197,354
30 Day Avg. Volume2,807,671
Financial Highlights & Ratios
PEG Ratio0.26
Price to Book (P/B)20.34
Price to Sales (P/S)4.79
P/FCF Ratio21.74
Enterprise Value/Market Cap1.16
Enterprise Value/Revenue6.17
Enterprise Value/Gross Profit8.63
Enterprise Value/Ebitda13.76
Forecast
1Y Price Target
$355.91Price Target Upside0.17% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering23
EPS Forecast (FY)22.35
Revenue Forecast (FY)$37.78B
Bulls Say, Bears Say
Bulls Say
Free Cash Flow GenerationConsistent, high FCF provides a durable funding base for R&D, manufacturing scale‑up, dividends, and buybacks without immediate equity issuance. Over 2–6 months this supports disciplined capital allocation, execution of launches and potential de‑leveraging or strategic M&A when opportunities fit.
High Biologics MarginsSustained high gross and net margins reflect pricing power, biologics manufacturing scale and a favorable product mix. These structural margins enable durable operating profitability, capacity to reinvest in pipeline and absorb mix shifts, supporting long‑term cash generation and shareholder returns.
Diversified Growth Drivers & PipelineMultiple fast‑growing products and advancing late‑stage assets reduce reliance on any single franchise. Coupled with targeted capex and AI gains boosting R&D and manufacturing productivity, this structural diversification increases probability of sustaining revenue and margin recovery over the medium term.
Bears Say
High LeverageMaterial leverage raises refinancing and interest rate sensitivity, constraining strategic flexibility. Even with robust FCF, debt levels imply multi‑year deleveraging or asset sales may be required to materially reduce solvency risk, limiting capacity for large acquisitions or sustained elevated buybacks.
Loss Of Exclusivity On Legacy Bone DrugsAccelerated biosimilar competition materially erodes a historically predictable cash franchise, increasing pressure on near‑term revenues. Replacing this revenue requires successful commercialization of newer assets, which elevates execution risk and increases dependence on pipeline timing and payer uptake.
Tax & Regulatory/Clinical UncertaintiesA potential material IRS adjustment, alongside FDA actions and paused trials noted in the call, creates structural financial statement and execution risk. Outcomes could affect deferred tax positions, cash tax payments and planning, and complicate forecasting and capital allocation over multiple quarters.
Amgen News
AMGN FAQ
What was Amgen Inc’s price range in the past 12 months?
Amgen Inc lowest stock price was $269.77 and its highest was $391.29 in the past 12 months.
What is Amgen Inc’s market cap?
Amgen Inc’s market cap is $198.61B.
When is Amgen Inc’s upcoming earnings report date?
Amgen Inc’s upcoming earnings report date is Aug 04, 2026 which is in 24 days.
How were Amgen Inc’s earnings last quarter?
Amgen Inc released its earnings results on Apr 30, 2026. The company reported $5.15 earnings per share for the quarter, beating the consensus estimate of $4.767 by $0.383.
Is Amgen Inc overvalued?
According to Wall Street analysts Amgen Inc’s price is currently Undervalued.
Does Amgen Inc pay dividends?
Amgen Inc pays a Quarterly dividend of $2.52 which represents an annual dividend yield of 3%. See more information on Amgen Inc dividends here
What is Amgen Inc’s EPS estimate?
Amgen Inc’s EPS estimate is 5.6.
How many shares outstanding does Amgen Inc have?
Amgen Inc has 539,708,250 shares outstanding.
What happened to Amgen Inc’s price movement after its last earnings report?
Amgen Inc reported an EPS of $5.15 in its last earnings report, beating expectations of $4.767. Following the earnings report the stock price went down -4.745%.
Which hedge fund is a major shareholder of Amgen Inc?
Currently, no hedge funds are holding shares in AMGN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Amgen Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$355.91 (0.17% Upside)
$355.91 (0.17% Upside)
Blogger Sentiment
Bullish
AMGN Sentiment 70%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Increased
By 644.1K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 0.6%
Last 30 Days ▲ 4.3%
Last 30 Days ▲ 4.3%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
26.31%
12-Months-Change
Fundamentals
Return on Equity
89.41%
Trailing 12-Months
Asset Growth
3.51%
Trailing 12-Months
Company Description
Amgen Inc
Amgen Inc., established in 1980 and headquartered in Thousand Oaks, California, is a global biotechnology leader focused on discovering, developing, manufacturing, and delivering groundbreaking human medicines. The company's scientific endeavors span several critical therapeutic categories, including inflammatory conditions, oncology and hematology, bone health, cardiovascular diseases, nephrology, and neuroscience. Its extensive portfolio features a range of significant pharmaceutical products. Notable examples include Enbrel, prescribed for conditions like plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta, which helps cancer patients by reducing the risk of infection linked to a low white blood cell count; Prolia, utilized in postmenopausal women to combat osteoporosis; and Xgeva, designed to prevent skeletal-related complications. Otezla offers relief for adult patients suffering from plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease. Aranesp addresses anemia and low red blood cell counts, while KYPROLIS is employed to treat patients with relapsed or refractory multiple myeloma. Furthermore, Repatha plays a vital role in lowering the incidence of major cardiovascular events such as myocardial infarction, stroke, and coronary revascularization. Amgen's comprehensive product lineup also encompasses Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. The company distributes its therapies worldwide, primarily serving healthcare providers, including physicians and their clinics, dialysis centers, hospitals, and pharmacies. Distribution is facilitated through pharmaceutical wholesale distributors, complemented by direct-to-consumer channels. Amgen actively engages in strategic collaborations. It has partnered with entities such as Novartis Pharma AG, UCB, Bayer HealthCare LLC, BeiGene, Ltd., Eli Lilly and Company, Datos Health, and Verastem, Inc., to jointly assess VS-6766 when combined with lumakrastm (Sotorasib) in patients with KRAS G12C-mutant non-small cell lung cancer. Another key alliance involves Kyowa Kirin Co., Ltd., for the co-development and commercialization of KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody targeting atopic dermatitis and other autoimmune conditions. Additionally, Amgen maintains research and development partnerships with Neumora Therapeutics, Inc. and Plexium, Inc.
AMGN Company Deck
AMGN Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed a broadly positive tone: Amgen reported modest overall product sales growth (4%) while its six key growth drivers delivered strong momentum (24% aggregate growth and ~70% of sales), the company raised full-year revenue and EPS guidance, generated substantial free cash flow, and highlighted significant pipeline progress (notably Meritide, olpasiran, Imdeltra, TEPEZZA) and AI-driven R&D productivity gains. Material challenges were acknowledged, including steep declines in legacy osteoporosis brands (Prolia/XGEVA), rising cost-of-sales pressure, regulatory and trial uncertainties (Tabneos/paused blinatumomab enrollment), and a potentially material IRS audit adjustment for tax years 2016–2018. Overall, the positive commercial momentum, strengthened guidance, robust cash generation, and advancing late-stage pipeline outweigh the notable headwinds and risks discussed during the call.View all AMGN earnings summariesAMGN Revenue Breakdown
13.09% Prolia
9.92% Enbrel
6.66% XGEVA
6.65% Repatha
63.69% Other
AMGN Stock 12 Month Forecast
Average Price Target
$355.91
▲(0.17% Upside)
Technical Analysis
Ownership Overview
0.21% Insiders
24.29% Mutual Funds
0.41% Other Institutional Investors
44.46% Public Companies and Individual Investors